ARCA biopharma, Inc.

NasdaqCM:ABIO Stok Raporu

Piyasa değeri: US$50.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ARCA biopharma Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Tom Keuer

İcra Kurulu Başkanı

US$400.8k

Toplam tazminat

CEO maaş yüzdesi84.8%
CEO görev süresi9.7yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi7.5yrs

Son yönetim güncellemeleri

Recent updates

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Apr 04
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Sep 24
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 03

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Mar 18
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Nov 27
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

CEO Tazminat Analizi

Tom Keuer'un ücretlendirmesi ARCA biopharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$401kUS$340k

-US$5m

Sep 30 2023n/an/a

-US$5m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$449kUS$340k

-US$10m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$421kUS$339k

-US$19m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$16m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$631kUS$285k

-US$10m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$304kUS$283k

-US$5m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$327kUS$303k

-US$8m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$457kUS$302k

-US$18m

Tazminat ve Piyasa: Tom 'nin toplam tazminatı ($USD 400.80K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 653.78K ).

Tazminat ve Kazançlar: Tom 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tom Keuer (65 yo)

9.7yrs

Görev süresi

US$400,802

Tazminat

Mr. Thomas A. Keuer, also known as Tom, serves as President & Principal Executive Officer of ARCA Biopharma, Inc. since April 3, 2024 and has been the Chief Operating Officer since December 1, 2014. Mr. Ke...

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Linda Grais
Independent Director17.3yrsUS$162.50k0%
$ 0
Anders Hove
Independent Director7.5yrsUS$150.00k0%
$ 0
Robert Conway
Independent Chairman of the Board10.9yrsUS$195.00k0.34%
$ 174.5k
Jacob Ma-Weaver
Director2.2yrsUS$130.00kVeri yok
James Flynn
Independent Director1.7yrsUS$40.00k0%
$ 0

7.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ABIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).